G-Neostigmine Injection

G-G-Neostigmine is indicated for-

• The symptomatic control of myasthenia gravis when oral therapy is impractical.
• The prevention and treatment of postoperative distention and urinary retention after mechanical obstruction has been excluded.
• Reversal of effects of nondepolarizing neuromuscular blocking agents (e.g., Tubocurarine, metocurine, gallamine or pancuronium) after surgery.

Neostigmine Methylsulfate Injection, an anticholinesterase agent is a sterile, nonpyrogenic solution of Neostigmine Methylsulfate in Water for Injections intended for intramuscular (IM), intravenous (IV) or subcutaneous (SC) administration.

Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. The drug inhibits acetylcholinesterase which is responsible for the degredation of acetylcholine. So, with acetylcholinesterase inhibited, more acetylcholine is present By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors which are involved in muscle contraction.. It does not cross the blood-brain barrier.

Antagonist to Nondepolarising Neuromuscular Blockade:

• Adults: A single dose of Neostigmine Methylsulfate injection 2 to 3 mg with atropine sulphate 0.6-1.2 mg by slow IV injection over 1 minute. The recommended ratio of atropine to Neostigmine Methylsulfate injection is 1:2 to 1:3. The maximum recommended dose of Neostigmine Methylsulfate injection in adults is 5 mg.
• Children: The suggested dose in children is 0.05 mg/kg/dose and atropine sulphate 0.02 mg/kg/dose by slow IV injection. Maximum recommended dose of Neostigmine Methylsulfate injection in children is 2.5 mg.

Myasthenia Gravis:

• Adults: 1 mg to 2.5 mg given IM or SC at intervals throughout the day when greater strength may be needed (e.g. mornings and before meals), given a total daily dose of 5 to 20 mg. Duration of action of a single dose is 2 to 4 hours.
• Neonates: 0.05-0.25 mg IM every 2-4 hours, half an hour before feeding. Treatment is not usually required beyond 8 weeks of age. Because the condition is usually self limiting the daily dosage should gradually be reduced until the medicine can be withdrawn.
• When large doses of Neostigmine Methylsulfate injection are given to myasthenic patients, atropine sulphate may be required to counteract the muscarinic side effects.

Urinary Retention:

• Prophylaxis: 0.25 mg SC or IM before or immediately after the operation, repeated every 4 to 6 hours for 2-3 days.
• Treatment: 0.5 mg SC or IM and apply warmth to lower abdomen. After patient has voided continue 0.5 mg SC or IM every 3 hours for at least 5 injections. If there has been no urinary response within one hour of the first dose, the patient should be catheterised.

G-Neostigmine Methylsulfate injection does not antagonize, and may in fact prolong, the Phase I block of depolarizing muscle relaxants such as succinylcholine or decamethonium. Certain antibiotics, especially neomycin, streptomycin and kanamycin, have a mild but definite nondepolarizing blocking action which may accentuate neuromuscular block.

These antibiotics should be used in the myasthenic patient only when definitely indicated, and then careful adjustment should be made of the anticholinesterase dosage. Local and some general anesthetics, antiarrhythmic agents and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis; the dose of G-Neostigmine Methylsulfate may have to be increased accordingly.

Neostigmine Methylsulfate injection is contraindicated in patients with known hypersensitivity to the drug. It is also contraindicated in patients with peritonitis or mechanical obstruction of the intestinal or urinary tract.

Adverse reactions generally associated with G-Neostigmine overdosage are:

• Cardiovascular: Cardiac arrhythmias (especially bradycardia), hypotension, cardiac arrest, syncope.
• Central Nervous System: Headache, dizziness, convulsions, loss of consciousness, coma, drowsiness, restlessness, ataxia, slurred speech, agitation and fear.
• Gastrointestinal: Nausea, vomiting, diarrhoea, flatulence, abdominal cramps, increased peristalsis and involuntary defaecation.
• Genitourinary: Involuntary urination or desire to urinate.
• Musculoskeletal: Muscle cramps, fasciculation, general weakness and paralysis. Respiratory: Increased oral, pharyngeal and bronchial secretion, dyspnoea, bronchospasm, respiratory depression, respiratory failure, tight chest and wheezing.
• Allergic: Allergic reactions including anaphylaxis.
• Skin: Rash and urticaria. Others: Increased sweating and salivation, miosis, vision changes, nystagmus and lacrimation.

Pregnancy Category C. There are no adequate or well-controlled studies of Neostigmine Methylsulfate in either laboratory animals or in pregnant women. It is not known whether Neostigmine Methylsulfate can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Neostigmine Methylsulfate should be given to a pregnant woman only if clearly needed.

Nonteratogenic Effects: Anticholinesterase drugs may cause uterine irritability and induce premature labor when given IV to pregnant women near term.

Use in Lactation: It is not known whether Neostigmine Methylsulfate is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from Neostigmine Methylsulfate in nursing infants, a decision should be made whether to discontinue nursing onto discontinue the drug, taking into account the importance of the drug to the mother

G-Neostigmine Methylsulfate should be used with caution in patients with epilepsy, bronchial asthma, bradycardia, recent coronary occlusion, vagotonia, hyperthyroidism, cardiac arrhythmias or peptic ulcer. When large doses of G-Neostigmine Methylsulfate are administered, the prior or simultaneous injection of atropine sulfate may be advisable. Separate syringes should be used for the G-Neostigmine Methylsulfate and atropine. Because of the possibility of hypersensitivity in an occasional patient, atropine and antishock medication should always be readily available.

Overdosage with G-Neostigmine Methylsulfate can cause cholinergic crisis, which is characterised by increasing muscle weakness. Myasthenic crisis is due to an increase in severity of the disease and may be difficult to distinguish from cholinergic crisis on a symptomatic basis. Cholinergic crisis can lead to respiratory paralysis, which may result in death, while myasthenic crisis is extreme muscle weakness. The differentiation between the two crises is extremely important as treatment is different for each. The two types of crises can be differentiated by the use of edrophonium and clinical judgement.

Anti-cholinesterases, Drugs used in Myasthenia Gravis

Store at controlled room temperature protected from light. Any portion of the contents remaining should be discarded.